Please assess the completion status of the following clinical trial:

Trial Title: Study of TG-C in Patients With Grade 3 Degenerative Joint Disease of the Knee

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or Female subject~2. Age 18 to 70 years~3. In general good health as evidenced by physical examination, normal hematology, serum chemistry, and urinalysis screening laboratory results, and a negative history of significant organ system disorders. All laboratory values must be within 20% of normal ranges.~   1. Body Mass Index (BMI) should be between '18.5 - 45.5'. The applied scale is the same for both men and women.~  2. Blood Pressure measurements - Systolic Blood Pressure should be between 90-160mm. Hg, and Diastolic Blood Pressure between 50-90mm.Hg,~4. Patients with Grade 3 chronic osteoarthritis of the knee as determined by the Radiographic Criteria of Kellgren and Lawrence.~5. Symptom of pain for more than four (4) consecutive months and intensity of ≥ 40 and ≤ 90 on the 100-mm scale.~6. Patients should be cleared to use protocol specified equipment: 3T MRI.~7. Patients providing written informed consent after the nature of the study is fully explained and understood by the patient.~Exclusion Criteria:~1. Age 71 or older~2. Patients with abnormal hematology, serum chemistry, or urinalysis screening laboratory results.~3. Patients taking non-steroidal anti-inflammatory medications within 14 days of baseline visit unless washed out as per section 3.6.4 above.~4. Patients taking steroidal anti-inflammatory medications within 2 months of baseline visit.~5. Patients with a recent (within 1 year) history of drug abuse and/or a positive urine drug test at the time of screening.~6. Patients receiving injections to the treated knee within 2 months prior to study entry~7. Patients who are contraindicated for 3T MRI.~8. Patients who are pregnant or currently breast-feeding children.~9. Patients with systemic, rheumatic or inflammatory disease of the knee or chondrocalcinosis, hemochromatosis, inflammatory arthritis, necrosis of the femoral condyle, arthropathy of the knee associated with juxta-articular Paget's disease of the femur or tibia, ochronosis, hemophilic arthropathy, infectious arthritis, Charcot's knee joint, villonodular synovitis, synovial chondromatosis, and/or history of inflammatory arthropathy.~10. Patients with ongoing infectious disease, including HIV and hepatitis B or C.~11. Patients with clinically significant cardiovascular, renal, hepatic, endocrine disease, cancer, or Type I diabetes.~12. Patients participating in a study of an experimental drug or medical device within 30 days of study entry.~13. Patients that will be unable to comply with the requisite study follow-up and are not able to complete all of the follow-up office visits and 3T MRI exams.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- TissueGene-C (Type: EXPERIMENTAL): TissueGene-C at 3 x 10e7 cells per injection (intraarticular)
- Placebo Control (Type: PLACEBO_COMPARATOR): Normal Saline injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete